ALEC vs DNLI
ALEC: Alector is a biotech firm pioneering blood-brain barrier delivery technologies to advance a diverse pipeline of therapeutic candidates for neurodegenerative diseases. DNLI: Denali Therapeutics is a clinical-stage biotechnology company developing blood-brain barrier-penetrating therapeutics to treat neurodegenerative and lysosomal storage diseases.
Side-by-side fundamentals
| Metric | ALEC | DNLI | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.02 | $18.67 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-08) | $226M | $3.0B | |
| Net margin FY2025, SEC XBRL | -679.2% | n/a | |
| Operating margin FY2025, SEC XBRL | -741.3% | n/a | |
| ROE FY2025, SEC XBRL | -466.3% | -50.6% | DNLI higher |
| ROA FY2025, SEC XBRL | -48.7% | -44.8% | DNLI higher |
| Debt / equity as of 2026-09-03 | 0.94 | 0.01 | DNLI lower |
| Revenue growth (YoY) as of 2026-09-03 | -79.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -46.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.55 | 1.46 | |
| 1-year return as of 2026-10-08 close | -34.4% | +19.3% | DNLI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.